We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

My Favourite 5%+ Yields: GlaxoSmithKline plc, Centrica PLC & Vodafone Group plc

Looking for a great dividend yield? Look no further than GlaxoSmithKline plc (LON:GSK), Centrica PLC (LON:CNA) & Vodafone Group plc (LON:VOD)

| More on:

You’re reading a free article with opinions that may differ from The Twelfth Magpie’s Premium Investing Services. Become a member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more, and get a free 'Best Buy Now' stock!.

Cash

Although there has been a lot of talk recently regarding interest rate rises, it seems clear that rates are unlikely to hit the ‘historic norm’ of 4%-5% for many years to come. Indeed, the Bank of England has even stated that 2%-3% could be the ‘new normal’. With that in mind, high-yielding shares could continue to offer a realistic alternative to savers and income-seeking investors alike. Here are three companies that yield at least 5% and trade at an attractive price.

Should you buy Centrica Plc shares today?

Before you decide, please take a moment to review this report first. Despite ongoing uncertainties from US tariffs to global conflicts, Mark Rogers and his team believe many UK shares still trade at substantial discounts, offering savvy investors plenty of potential opportunities to learn about.

That’s why this could be an ideal time to secure this valuable research – Mark’s analysts have scoured the markets to reveal 5 of his favourite long-term ‘Buys’. Please, don’t make any big decisions before seeing them.

GlaxoSmithKline

GlaxoSmithKline (LSE: GSK) continues to see its share price underperform due to weak sentiment rather than doubts surrounding its long term potential. The pharmaceutical giant is subject to various bribery allegations that have caused shares in the company to fall by 8% in the last three months alone.

However, with a highly diversified drugs pipeline that has huge potential, GlaxoSmithKline could see its share price rise over the longer term. In the meantime, a dividend yield of 5.5% is highly attractive, while a price to earnings (P/E) ratio of 13.1 highlights that the present time could be an opportunity to buy in at a low price.

Centrica

As with GlaxoSmithKline, Centrica (LSE: CNA) is suffering from weak sentiment. It is set to change its management team in the near future (with BP’s Iain Conn replacing Sam Laidlaw on 1 January 2015) and is subject to continuing uncertainty regarding domestic energy prices post the 2015 general election.

However, the market seems to pricing in these risks, with shares in Centrica currently trading on a P/E ratio of just 12 (versus 13.7 for the FTSE 100). Furthermore, shares in the company currently yield a highly impressive 5.5%, with dividends per share forecast to increase by 3.2% next year. Overall, Centrica seems to offer good value and considerable income potential.

Vodafone

Vodafone’s (LSE: VOD) current yield of 5.5% has come under a degree of scrutiny in recent months. That’s because it currently pays out more money as a dividend than it makes as a profit. As a result, the current level of dividend is unsustainable in the long run.

Despite this, Vodafone could prove to be an attractive income play. That’s because it appears to have a sound long term strategy that could deliver strong growth in profitability moving forward. Indeed, Vodafone’s purchase of high-quality, undervalued assets in Europe may take time to come good, but should ensure that the company is able to sustain an impressive yield in future years. As a result, it remains an attractive income play at current price levels.

Peter Stephens owns shares of Centrica and GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Close-up as a woman counts out modern British banknotes.
Investing Articles

How to buy growth stocks at below-market prices

Don’t want to pay market prices for growth stocks? Here's a sneaky strategy investors can use to get deals at…

Read more »

CEO Mark Zuckerberg at F8 2019 event
Investing Articles

Are Meta shares at the start of a comeback?

Shares in Meta Platforms have been held back by the firm’s high-risk approach to AI. But is this the moment…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

With dividend yields averaging above 7%, are these 2 UK shares worth considering?

Muhammad Cheema looks at two UK shares: ITV and Legal & General. With yields of 6.1% and 8.1%, should investors…

Read more »

Close-up as a woman counts out modern British banknotes.
Investing Articles

How much do you need to invest in dividend stocks to be able to retire?

Some 77% of people in the UK won't have enough income to manage a moderate retirement. Here’s how dividend stocks…

Read more »

Abstract bull climbing indicators on stock chart
Investing Articles

FTSE 250 stock CMC’s shares have rocketed 51%! What’s going on?

CMC Markets' shares have surged by double-digits today after a strong full-year trading update. Is the FTSE 250 company now…

Read more »

A row of satellite radars at night
Investing Articles

Will I buy SpaceX at £100 a share in my SIPP?

Ben McPoland is considering adding SpaceX stock to his SIPP on 12 June. Might this be a no-brainer buy-and-hold opportunity?

Read more »

Young brown woman delighted with what she sees on her screen
Investing Articles

Aberdeen shares are back in the FTSE 100 — is this turnaround stock just getting started?

Following its return to the FTSE 100, Andrew Mackie examines whether Aberdeen's shares could be on the cusp of a…

Read more »

Shot of an young mixed-race woman using her cellphone while out cycling through the city
Investing Articles

Down 65% with a 5.65% yield! Is this dividend share a once-in-a-decade buy? 

Harvey Jones says this dividend share is still posting decent profits at a challenging time. Its low valuation and high…

Read more »